{
    "guideline_identifier": "PIIS0923753425000730.txt",
    "cancer_focus": {
        "primary_cancer": "Hepatocellular Carcinoma (HCC)",
        "related_syndrome_or_condition": "Chronic liver disease, Cirrhosis, Chronic Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) infection, Portal hypertension, Metabolic dysfunction-associated steatotic liver disease (MASLD)"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "BCLC Stage 0 (Very Early): Single tumor <2 cm, Child-Pugh A, no portal hypertension",
            "risk_group": "Very early stage",
            "treatment_plans": [
                {
                    "clinical_context": "Solitary tumors without portal hypertension",
                    "recommendation_type": "Curative Therapy",
                    "recommendation_content": "Surgical resection (minimally invasive preferred)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IIA"
                },
                {
                    "clinical_context": "Tumors ≤3 cm",
                    "recommendation_type": "Curative Therapy",
                    "recommendation_content": "Thermal ablation (RFA/MWA)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IIA"
                }
            ]
        },
        {
            "staging_criteria": "BCLC Stage A (Early): Single tumor or ≤3 nodules ≤3 cm, Child-Pugh A–B",
            "risk_group": "Early stage",
            "treatment_plans": [
                {
                    "clinical_context": "Within Milan criteria",
                    "recommendation_type": "Curative Therapy",
                    "recommendation_content": "Orthotopic Liver Transplantation (OLT)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IIA"
                },
                {
                    "clinical_context": "Outside Milan criteria",
                    "recommendation_type": "Curative Therapy",
                    "recommendation_content": "Consider OLT under UCSF criteria",
                    "treatment_line": "Alternative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IIIB"
                },
                {
                    "clinical_context": "Waitlist >3 months for OLT",
                    "recommendation_type": "Bridge Therapy",
                    "recommendation_content": "Transarterial radioembolization (TARE)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IIIB"
                }
            ]
        },
        {
            "staging_criteria": "BCLC Stage B (Intermediate): Multinodular, asymptomatic, Child-Pugh A–B, preserved performance status",
            "risk_group": "Intermediate stage",
            "treatment_plans": [
                {
                    "clinical_context": "Multinodular HCC",
                    "recommendation_type": "Locoregional Therapy",
                    "recommendation_content": "Transarterial chemoembolization (TACE) with DEB preferred",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IB"
                },
                {
                    "clinical_context": "Alternative to TACE",
                    "recommendation_type": "Locoregional Therapy",
                    "recommendation_content": "Transarterial radioembolization (TARE)",
                    "treatment_line": "Alternative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IIB"
                },
                {
                    "clinical_context": "Ablation-unsuitable tumors",
                    "recommendation_type": "Radiotherapy",
                    "recommendation_content": "Stereotactic body radiotherapy (SBRT) or HDR brachytherapy",
                    "treatment_line": "Alternative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IIB"
                }
            ]
        },
        {
            "staging_criteria": "BCLC Stage C (Advanced): Vascular invasion/extrahepatic spread, PS 1–2, Child-Pugh A–B",
            "risk_group": "Advanced stage",
            "treatment_plans": [
                {
                    "clinical_context": "First-line systemic therapy (ECOG PS 0–1)",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Atezolizumab + bevacizumab",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IA"
                },
                {
                    "clinical_context": "First-line systemic therapy (ECOG PS 0–1)",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Durvalumab + tremelimumab (STRIDE regimen)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IA"
                },
                {
                    "clinical_context": "ICI contraindicated",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Lenvatinib or sorafenib",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IA"
                },
                {
                    "clinical_context": "Post-sorafenib therapy",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Regorafenib or cabozantinib",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IA"
                },
                {
                    "clinical_context": "Post-sorafenib with elevated AFP",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Ramucirumab",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "AFP",
                            "status": "≥400 ng/mL",
                            "testing_guidance": "Mandatory pre-treatment testing for eligibility"
                        }
                    ],
                    "esmo_evidence_level": "Level IB"
                }
            ]
        },
        {
            "staging_criteria": "BCLC Stage D (Terminal): Severe liver dysfunction (Child-Pugh C), PS >2",
            "risk_group": "Terminal stage",
            "treatment_plans": [
                {
                    "clinical_context": "Symptomatic management",
                    "recommendation_type": "Supportive Care",
                    "recommendation_content": "Best supportive care (BSC)",
                    "treatment_line": "Palliative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Pain management",
                    "recommendation_type": "Radiotherapy",
                    "recommendation_content": "Stereotactic radiotherapy for pain control",
                    "treatment_line": "Palliative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IIA"
                }
            ]
        },
        {
            "staging_criteria": "Post-curative treatment (Resection/Ablation/OLT)",
            "risk_group": "Adjuvant setting",
            "treatment_plans": [
                {
                    "clinical_context": "After resection/ablation",
                    "recommendation_type": "Adjuvant Therapy",
                    "recommendation_content": "Adjuvant therapy not recommended",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IE"
                },
                {
                    "clinical_context": "After OLT",
                    "recommendation_type": "Adjuvant Therapy",
                    "recommendation_content": "Adjuvant therapy not recommended",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IVE"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "AFP ≥400 ng/mL predicts efficacy of ramucirumab. No validated predictive biomarkers for immune checkpoint inhibitor (ICI) efficacy. Biopsy required for non-cirrhotic patients and prior to systemic therapy in advanced HCC. Molecular testing via NGS recommended for mixed-histology tumors and clinical trial enrollment."
    }
}